Prednisolone side effects: what 179,370 FDA adverse event reports show
Who reports
179,370 reports · 96% serious · 28,710 with death outcome · 53% female
Used for
Prednisolone Oral Solution USP is indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable: in infancy mineralocorticoid supplementation is of particular importance).
What it is
Prednisolone is a glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,266 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Alveolar proteinosis | 183 | 53.0 44.5–63.1ROR 53.0 · calibrated p 1e-5 ✓ | 36.4 EB05 32.2 · IC025 +4.8 3/3 methods agree vs other Corticosteroids: PRR 38.6 (32.3–46.1) | Not in label — unassessed | serious n=182 · 100% clinician | no trial arm names this drug |
| Parvovirus b19 infection | 275 | 52.9 45.8–61.0ROR 52.9 · calibrated p 1e-5 ✓ | 36.4 EB05 32.9 · IC025 +4.9 3/3 methods agree vs other Corticosteroids: PRR 30.7 (26.7–35.3) | Not in label — unassessed | serious n=222 · 100% clinician | no trial arm names this drug |
| C-reactive protein | 269 | 49.1 42.5–56.6ROR 49.1 · calibrated p 2e-5 ✓ | 34.6 EB05 31.2 · IC025 +4.8 3/3 methods agree vs other Corticosteroids: PRR 3.5 (3.1–3.9) | Lab value / disease marker | serious n=269 · ♀ 100% (drug 53%) · 100% clinician | no trial arm names this drug |
| Deep vein thrombosis postoperative | 542 | 44.5 40.3–49.1ROR 44.6 · calibrated p 3e-5 ✓ | 32.3 EB05 30.0 · IC025 +4.8 3/3 methods agree vs other Corticosteroids: PRR 3.2 (2.9–3.5) | Not in label — unassessed | serious n=542 · ♀ 100% (drug 53%) · 95% clinician | no trial arm names this drug |
| Pulmonary nocardiosis | 224 | 43.9 37.7–51.3ROR 44.0 · calibrated p 3e-5 ✓ | 31.9 EB05 28.6 · IC025 +4.7 3/3 methods agree vs other Corticosteroids: PRR 27.6 (23.7–32.1) | Not in label — unassessed | serious n=224 · ♀ 33% (drug 53%) · 100% clinician | no trial arm names this drug |
| Polyomavirus viraemia | 257 | 40.3 34.9–46.4ROR 40.3 · calibrated p 5e-5 ✓ | 30.0 EB05 27.0 · IC025 +4.6 3/3 methods agree vs other Corticosteroids: PRR 28.8 (25.0–33.3) | Not in label — unassessed | serious n=256 · 100% clinician | no trial arm names this drug |
| Steroid diabetes | 373 | 40.0 35.5–45.0ROR 40.1 · calibrated p 5e-5 ✓ | 29.8 EB05 27.4 · IC025 +4.7 3/3 methods agree vs other Corticosteroids: PRR 14.9 (13.4–16.7) | Labeled (related wording) related wording | serious n=373 · 100% clinician | no trial arm names this drug |
| Hepatitis e | 378 | 36.9 32.9–41.4ROR 37.0 · calibrated p 9e-5 ✓ | 28.1 EB05 25.8 · IC025 +4.6 3/3 methods agree vs other Corticosteroids: PRR 38.6 (34.1–43.6) | Labeled (related wording) related wording | serious n=377 · 100% clinician | no trial arm names this drug |
| Strongyloidiasis | 389 | 36.7 32.8–41.2ROR 36.8 · calibrated p 9e-5 ✓ | 28.0 EB05 25.8 · IC025 +4.6 3/3 methods agree vs other Corticosteroids: PRR 12.2 (11.0–13.6) | Not in label — unassessed | serious n=387 · ♀ 33% (drug 53%) · 100% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody | 153 | 34.6 28.9–41.4ROR 34.6 · calibrated p 1e-4 ✓ | 26.7 EB05 23.3 · IC025 +4.4 3/3 methods agree vs other Corticosteroids: PRR 2.6 (2.2–3.1) | Lab value / disease marker | serious n=153 · ♀ 100% (drug 53%) · 100% clinician | no trial arm names this drug |
| Polyomavirus-associated nephropathy | 526 | 34.0 30.9–37.5ROR 34.1 · calibrated p 1e-4 ✓ | 26.4 EB05 24.6 · IC025 +4.5 3/3 methods agree vs other Corticosteroids: PRR 16.8 (15.3–18.5) | Likely indication confounding shares a disease stem with the indications wording | serious n=526 · ♀ 33% (drug 53%) · 100% clinician | no trial arm names this drug |
| Pneumocystis jiroveci pneumonia | 510 | 33.9 30.8–37.5ROR 34.0 · calibrated p 1e-4 ✓ | 26.4 EB05 24.5 · IC025 +4.5 3/3 methods agree vs other Corticosteroids: PRR 36.0 (32.4–39.9) | Likely indication confounding shares a disease stem with the indications wording | serious n=507 · 95% clinician | no trial arm names this drug |
| Mycobacterium chelonae infection | 164 | 33.3 28.0–39.6ROR 33.3 · calibrated p 2e-4 ✓ | 26.0 EB05 22.8 · IC025 +4.3 3/3 methods agree vs other Corticosteroids: PRR 5.4 (4.7–6.4) | Not in label — unassessed | serious n=164 · 100% clinician | no trial arm names this drug |
| Nocardiosis | 550 | 31.8 28.9–34.9ROR 31.9 · calibrated p 2e-4 ✓ | 25.1 EB05 23.4 · IC025 +4.5 3/3 methods agree vs other Corticosteroids: PRR 17.1 (15.6–18.7) | Labeled (related wording) related wording | serious n=550 · 94% clinician | no trial arm names this drug |
| Disseminated cryptococcosis | 148 | 29.3 24.4–35.1ROR 29.3 · calibrated p 3e-4 ✓ | 23.5 EB05 20.5 · IC025 +4.2 3/3 methods agree vs other Corticosteroids: PRR 37.8 (31.1–46.0) | Not in label — unassessed | serious n=148 · ♀ 0% (drug 53%) · 100% clinician | no trial arm names this drug |
| Complications of transplanted kidney | 435 | 28.2 25.4–31.3ROR 28.2 · calibrated p 4e-4 ✓ | 22.8 EB05 21.0 · IC025 +4.3 3/3 methods agree vs other Corticosteroids: PRR 18.3 (16.5–20.3) | Not in label — unassessed | serious n=432 · ♀ 31% (drug 53%) · 91% clinician | no trial arm names this drug |
| Cytomegalovirus enterocolitis | 148 | 28.0 23.4–33.5ROR 28.0 · calibrated p 4e-4 ✓ | 22.6 EB05 19.7 · IC025 +4.1 3/3 methods agree vs other Corticosteroids: PRR 38.6 (31.7–47.0) | Not in label — unassessed | serious n=148 · ♀ 0% (drug 53%) · 100% clinician | no trial arm names this drug |
| Diffuse large b-cell lymphoma refractory | 178 | 27.5 23.4–32.4ROR 27.5 · calibrated p 4e-4 ✓ | 22.3 EB05 19.7 · IC025 +4.2 3/3 methods agree vs other Corticosteroids: PRR 22.1 (18.7–26.1) | Likely indication confounding shares a disease stem with the indications wording | serious n=178 · 100% clinician | no trial arm names this drug |
| Post transplant lymphoproliferative disorder | 957 | 27.4 25.5–29.4ROR 27.5 · calibrated p 4e-4 ✓ | 22.3 EB05 21.1 · IC025 +4.4 3/3 methods agree vs other Corticosteroids: PRR 16.2 (15.1–17.4) | Likely indication confounding shares a disease stem with the indications wording | serious n=957 · 100% clinician | no trial arm names this drug |
| Delayed graft function | 134 | 27.2 22.5–32.8ROR 27.2 · calibrated p 5e-4 ✓ | 22.1 EB05 19.1 · IC025 +4.1 3/3 methods agree vs other Corticosteroids: PRR 22.2 (18.3–26.9) | Not in label — unassessed | serious n=134 · ♀ 0% (drug 53%) · 100% clinician | no trial arm names this drug |
| Epstein-barr virus associated lymphoproliferative disorder | 333 | 26.9 23.9–30.3ROR 26.9 · calibrated p 5e-4 ✓ | 21.9 EB05 20.0 · IC025 +4.2 3/3 methods agree vs other Corticosteroids: PRR 30.6 (27.0–34.7) | Likely indication confounding shares a disease stem with the indications wording | serious n=332 · 100% clinician | no trial arm names this drug |
| Varicella zoster virus infection | 387 | 26.8 24.0–29.9ROR 26.9 · calibrated p 5e-4 ✓ | 21.9 EB05 20.1 · IC025 +4.2 3/3 methods agree vs other Corticosteroids: PRR 20.3 (18.1–22.6) | Labeled (related wording) related wording | serious n=386 · 100% clinician | no trial arm names this drug |
| Cytomegalovirus colitis | 422 | 26.6 23.9–29.6ROR 26.7 · calibrated p 5e-4 ✓ | 21.8 EB05 20.1 · IC025 +4.2 3/3 methods agree vs other Corticosteroids: PRR 18.8 (16.9–20.9) | Likely indication confounding shares a disease stem with the indications wording | serious n=422 · 94% clinician | no trial arm names this drug |
| X-ray abnormal | 325 | 25.9 22.9–29.2ROR 25.9 · calibrated p 6e-4 ✓ | 21.3 EB05 19.4 · IC025 +4.2 3/3 methods agree vs other Corticosteroids: PRR 3.1 (2.7–3.4) | Lab value / disease marker | serious n=325 · ♀ 100% (drug 53%) · 100% clinician | no trial arm names this drug |
| Infection in an immunocompromised host | 130 | 25.7 21.2–31.1ROR 25.7 · calibrated p 7e-4 ✓ | 21.1 EB05 18.2 · IC025 +4.0 3/3 methods agree vs other Corticosteroids: PRR 38.6 (31.3–47.6) | Not in label — unassessed | serious n=130 · ♀ 0% (drug 53%) · 100% clinician | no trial arm names this drug |
| Infection reactivation | 207 | 25.6 22.1–29.8ROR 25.7 · calibrated p 6e-4 ✓ | 21.1 EB05 18.8 · IC025 +4.1 3/3 methods agree vs other Corticosteroids: PRR 27.9 (23.8–32.7) | Labeled (related wording) related wording | serious n=207 · 100% clinician | no trial arm names this drug |
| Jc virus infection | 284 | 25.1 22.1–28.6ROR 25.2 · calibrated p 7e-4 ✓ | 20.7 EB05 18.8 · IC025 +4.1 3/3 methods agree vs other Corticosteroids: PRR 24.7 (21.7–28.3) | Labeled (related wording) related wording | serious n=284 · 100% clinician | no trial arm names this drug |
| Lupus vulgaris | 210 | 24.9 21.4–28.9ROR 24.9 · calibrated p 7e-4 ✓ | 20.6 EB05 18.4 · IC025 +4.1 3/3 methods agree vs other Corticosteroids: PRR 2.1 (1.8–2.4) | Not in label — unassessed | serious n=210 · ♀ 100% (drug 53%) · 100% clinician | no trial arm names this drug |
| Pneumocystis jirovecii pneumonia | 1,760 | 24.8 23.6–26.1ROR 25.1 · calibrated p 7e-4 ✓ | 20.6 EB05 19.8 · IC025 +4.3 3/3 methods agree vs other Corticosteroids: PRR 14.3 (13.6–15.1) | Likely indication confounding shares a disease stem with the indications wording | age-adj. PRR 19.3 · serious PRR 12.4 · 96% clinician | no trial arm names this drug |
| Lymphoproliferative disorder | 514 | 24.6 22.4–27.1ROR 24.7 · calibrated p 7e-4 ✓ | 20.4 EB05 19.0 · IC025 +4.2 3/3 methods agree vs other Corticosteroids: PRR 38.6 (34.7–42.9) | Likely indication confounding shares a disease stem with the indications wording | serious n=512 · 100% clinician | no trial arm names this drug |
| Chronic allograft nephropathy | 133 | 23.6 19.6–28.4ROR 23.6 · calibrated p 1e-3 ✓ | 19.7 EB05 17.0 · IC025 +3.9 3/3 methods agree vs other Corticosteroids: PRR 38.6 (31.4–47.5) | Likely indication confounding shares a disease stem with the indications wording | serious n=133 · ♀ 0% (drug 53%) · 100% clinician | no trial arm names this drug |
| Immunosuppressant drug level decreased | 199 | 23.3 20.0–27.2ROR 23.3 · calibrated p 0.001 ✓ | 19.5 EB05 17.3 · IC025 +4.0 3/3 methods agree vs other Corticosteroids: PRR 38.6 (32.6–45.7) | Lab value / disease marker | serious n=196 | no trial arm names this drug |
| Swollen joint count increased | 520 | 23.2 21.1–25.5ROR 23.3 · calibrated p 1e-3 ✓ | 19.5 EB05 18.1 · IC025 +4.1 3/3 methods agree vs other Corticosteroids: PRR 2.1 (1.9–2.3) | Lab value / disease marker | serious n=520 · ♀ 100% (drug 53%) · 95% clinician | no trial arm names this drug |
| Cryptococcosis | 262 | 22.6 19.8–25.8ROR 22.6 · calibrated p 0.001 ✓ | 19.0 EB05 17.1 · IC025 +4.0 3/3 methods agree vs other Corticosteroids: PRR 17.1 (15.0–19.6) | Not in label — unassessed | serious n=262 · ♀ 0% (drug 53%) · 100% clinician | no trial arm names this drug |
| Transplant rejection | 1,301 | 22.5 21.2–23.9ROR 22.7 · calibrated p 0.001 ✓ | 19.0 EB05 18.1 · IC025 +4.1 3/3 methods agree vs other Corticosteroids: PRR 17.1 (16.1–18.1) | Not in label — unassessed | serious PRR 11.5 | no trial arm names this drug |
| Bk virus infection | 535 | 22.1 20.1–24.2ROR 22.1 · calibrated p 0.001 ✓ | 18.7 EB05 17.4 · IC025 +4.1 3/3 methods agree vs other Corticosteroids: PRR 16.0 (14.6–17.6) | Labeled (related wording) related wording | serious n=527 · 100% clinician | no trial arm names this drug |
| Viraemia | 222 | 22.0 19.1–25.4ROR 22.1 · calibrated p 0.001 ✓ | 18.6 EB05 16.6 · IC025 +3.9 3/3 methods agree vs other Corticosteroids: PRR 10.9 (9.5–12.6) | Not in label — unassessed | serious n=216 · 100% clinician | no trial arm names this drug |
| Epstein-barr virus infection reactivation | 199 | 21.7 18.6–25.2ROR 21.7 · calibrated p 0.001 ✓ | 18.4 EB05 16.3 · IC025 +3.9 3/3 methods agree vs other Corticosteroids: PRR 25.6 (21.8–30.0) | Labeled (related wording) related wording | serious n=199 · 100% clinician | no trial arm names this drug |
| Kidney transplant rejection | 754 | 21.5 19.9–23.3ROR 21.6 · calibrated p 0.001 ✓ | 18.3 EB05 17.2 · IC025 +4.1 3/3 methods agree vs other Corticosteroids: PRR 16.8 (15.5–18.1) | Not in label — unassessed | serious n=754 | no trial arm names this drug |
| Adjustment disorder with depressed mood | 313 | 21.3 18.9–24.1ROR 21.4 · calibrated p 0.001 ✓ | 18.1 EB05 16.5 · IC025 +4.0 3/3 methods agree vs other Corticosteroids: PRR 2.4 (2.1–2.6) | Not in label — unassessed | serious n=313 · ♀ 100% (drug 53%) · 100% clinician | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Opportunistic infection | 7,388 | 6.66.5–6.8 | signal |
| Interstitial lung disease | 4,255 | 5.45.2–5.5 | signal |
| Neutropenia / agranulocytosis | 7,483 | 3.63.5–3.7 | signal |
| Osteonecrosis | 1,722 | 3.63.4–3.7 | signal |
| Severe cutaneous reaction | 1,986 | 3.23.0–3.3 | signal |
| Liver injury | 7,297 | 2.92.8–2.9 | signal |
| Serious infection | 18,570 | 2.92.8–2.9 | signal |
| Thrombocytopenia | 5,175 | 2.82.7–2.9 | signal |
| Kidney injury | 9,572 | 2.52.4–2.5 | signal |
| Hyponatraemia | 1,599 | 2.32.2–2.5 | signal |
| Tendon disorder | 756 | 2.32.2–2.5 | signal |
| Anaemia | 5,783 | 2.32.2–2.3 | signal |
| Rhabdomyolysis / myopathy | 1,474 | 2.12.0–2.3 | signal |
| Gi bleeding | 2,943 | 1.91.8–2.0 | raised |
| Pancreatitis | 1,290 | 1.91.8–2.0 | raised |
| Anaphylaxis / angioedema | 1,772 | 1.71.6–1.7 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Off label use (used outside approved label) | 15,547 | 2.1 2.1–2.1ROR 2.2 · calibrated p 0.942 | 2.1 EB05 2.1 · IC025 +1.0 3/3 methods agree vs other Corticosteroids: PRR 4.6 (4.6–4.7) | Reporting / coding artifact | age-adj. PRR 1.9 · serious PRR 2.2 · 90% clinician | no trial arm names this drug |
| Drug ineffective (drug did not work) | 12,806 | 1.1 1.1–1.2ROR 1.1 · calibrated p 0.405 | 1.1 EB05 1.1 · IC025 +0.2 vs other Corticosteroids: PRR 4.2 (4.2–4.3) | Reporting / coding artifact | age-adj. PRR 1.4 · serious PRR 1.8 | no trial arm names this drug |
| Pyrexia (fever) | 8,461 | 2.9 2.8–3.0ROR 3.0 · calibrated p 0.627 | 2.9 EB05 2.8 · IC025 +1.5 3/3 methods agree vs other Corticosteroids: PRR 5.8 (5.7–5.9) | Not in label — unassessed | age-adj. PRR 2.3 · serious PRR 2.1 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 7,071 | 1.5 1.4–1.5ROR 1.5 · calibrated p 0.633 | 1.5 EB05 1.4 · IC025 +0.5 vs other Corticosteroids: PRR 4.2 (4.1–4.3) | Not in label — unassessed | age-adj. PRR 1.3 · serious PRR 1.2 | no trial arm names this drug |
| Pneumonia (lung infection) | 6,979 | 2.6 2.5–2.6ROR 2.6 · calibrated p 0.763 | 2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree vs other Corticosteroids: PRR 5.3 (5.2–5.4) | Labeled (related wording) related wording | age-adj. PRR 2.1 · serious PRR 1.6 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 6,768 | 1.2 1.2–1.3ROR 1.2 · calibrated p 0.468 | 1.2 EB05 1.2 · IC025 +0.3 vs other Corticosteroids: PRR 4.1 (4.1–4.2) | Labeled adverse reaction exact term | age-adj. PRR 1.1 · serious PRR 1.3 | no trial arm names this drug |
| Condition aggravated | 6,029 | 2.4 2.3–2.4ROR 2.4 · calibrated p 0.853 | 2.3 EB05 2.3 · IC025 +1.2 3/3 methods agree vs other Corticosteroids: PRR 3.8 (3.7–3.9) | Reporting / coding artifact | age-adj. PRR 2.1 · serious PRR 2.1 | no trial arm names this drug |
| Nausea | 5,565 | 0.8 0.8–0.8ROR 0.8 · calibrated p 0.194 | 0.8 EB05 0.8 · IC025 -0.3 PRR-only: not supported by EBGM or IC vs other Corticosteroids: PRR 3.3 (3.3–3.4) | Not in label — unassessed | age-adj. PRR 0.7 · serious PRR 0.9 | no trial arm names this drug |
| Vomiting | 5,158 | 1.3 1.3–1.3ROR 1.3 · calibrated p 0.506 | 1.3 EB05 1.3 · IC025 +0.3 vs other Corticosteroids: PRR 4.1 (4.0–4.3) | Not in label — unassessed | age-adj. PRR 1.1 · serious PRR 1.1 | no trial arm names this drug |
| Fatigue (tiredness) | 5,130 | 0.8 0.7–0.8ROR 0.8 · calibrated p 0.164 | 0.8 EB05 0.8 · IC025 -0.4 PRR-only: not supported by EBGM or IC vs other Corticosteroids: PRR 2.4 (2.4–2.5) | Not in label — unassessed | age-adj. PRR 0.7 · serious PRR 0.8 | no trial arm names this drug |
| Product use in unapproved indication | 5,025 | 2.4 2.4–2.5ROR 2.5 · calibrated p 0.823 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree vs other Corticosteroids: PRR 5.6 (5.4–5.7) | Reporting / coding artifact | age-adj. PRR 2.3 · serious PRR 3.1 · 92% clinician | no trial arm names this drug |
| Headache | 4,664 | 0.9 0.8–0.9ROR 0.9 · calibrated p 0.222 | 0.9 EB05 0.9 · IC025 -0.2 PRR-only: not supported by EBGM or IC vs other Corticosteroids: PRR 3.2 (3.1–3.3) | Labeled adverse reaction exact term | age-adj. PRR 0.8 · serious PRR 1.0 · ♀ 74% (drug 53%) | no trial arm names this drug |
| Sepsis (blood infection) | 4,576 | 5.0 4.8–5.1ROR 5.1 · calibrated p 0.228 | 4.8 EB05 4.7 · IC025 +2.2 3/3 methods agree vs other Corticosteroids: PRR 8.6 (8.4–8.9) | Not in label — unassessed | age-adj. PRR 3.9 · serious PRR 2.9 · 92% clinician | no trial arm names this drug |
| Rash | 4,409 | 1.2 1.2–1.2ROR 1.2 · calibrated p 0.437 | 1.2 EB05 1.2 · IC025 +0.2 vs other Corticosteroids: PRR 3.0 (2.9–3.0) | Not in label — unassessed | age-adj. PRR 1.1 · serious PRR 1.5 | no trial arm names this drug |
| Arthralgia (joint pain) | 4,313 | 1.2 1.2–1.3ROR 1.2 · calibrated p 0.457 | 1.2 EB05 1.2 · IC025 +0.2 vs other Corticosteroids: PRR 2.9 (2.8–3.0) | Not in label — unassessed | age-adj. PRR 1.1 · serious PRR 1.3 · ♀ 76% (drug 53%) | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Alveolar proteinosis — n=183, PRR 53.0
- Parvovirus b19 infection — n=275, PRR 52.9
- Deep vein thrombosis postoperative — n=542, PRR 44.5
- Pulmonary nocardiosis — n=224, PRR 43.9
- Polyomavirus viraemia — n=257, PRR 40.3
- Strongyloidiasis — n=389, PRR 36.7
- Mycobacterium chelonae infection — n=164, PRR 33.3
- Disseminated cryptococcosis — n=148, PRR 29.3
- Complications of transplanted kidney — n=435, PRR 28.2
- Cytomegalovirus enterocolitis — n=148, PRR 28.0
✓ A hand-written Bradford Hill causality assessment exists for this drug: Corticosteroids (prednisolone) ↔ Avascular necrosis of bone.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Prednisolone?
In FDA FAERS, the most frequently co-reported reaction terms for Prednisolone are pyrexia, dyspnoea, pneumonia, diarrhoea, nausea, vomiting. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Prednisolone have an FDA boxed warning?
No. The FDA label retrieved for Prednisolone has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Prednisolone causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 35f0b197-c3ae-445a-8da7-9ffcd4472e05, effective 20260123; matched on
openfda.generic_name.exact:"PREDNISOLONE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 5755 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,306 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
PREDNISOLONE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.